These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23624839)

  • 1. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
    Iwanami A; Cloughesy TF; Cavenee WK; Mischel PS
    Cell Cycle; 2013 May; 12(10):1473-4. PubMed ID: 23624839
    [No Abstract]   [Full Text] [Related]  

  • 2. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
    Iwanami A; Gini B; Zanca C; Matsutani T; Assuncao A; Nael A; Dang J; Yang H; Zhu S; Kohyama J; Kitabayashi I; Cavenee WK; Cloughesy TF; Furnari FB; Nakamura M; Toyama Y; Okano H; Mischel PS
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4339-44. PubMed ID: 23440206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 4. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
    Asou N
    Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
    [No Abstract]   [Full Text] [Related]  

  • 5. Arsenic trioxide and neuroblastoma cytotoxicity.
    Pettersson HM; Karlsson J; Pietras A; Øra I; Påhlman S
    J Bioenerg Biomembr; 2007 Feb; 39(1):35-41. PubMed ID: 17549641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 7. Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
    Spencer A; Firkin F
    Aust N Z J Med; 1999 Jun; 29(3):385-6. PubMed ID: 10868510
    [No Abstract]   [Full Text] [Related]  

  • 8. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 9. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
    Tajima M
    Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
    [No Abstract]   [Full Text] [Related]  

  • 11. Arsenic: a new place?
    Vincent PC
    Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
    [No Abstract]   [Full Text] [Related]  

  • 12. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
    [No Abstract]   [Full Text] [Related]  

  • 13. Sweet fruit from a poisonous kiss.
    Liu D
    J Hematol Oncol; 2010 May; 3():19. PubMed ID: 20509866
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
    Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic compound approved as cancer chemotherapy agent.
    Miller JL
    Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
    [No Abstract]   [Full Text] [Related]  

  • 17. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Haanen C; Vermes I
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Br J Haematol; 2001 Apr; 113(1):257-8. PubMed ID: 11360894
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Powell BL
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
    [No Abstract]   [Full Text] [Related]  

  • 20. Arsenic-induced APL differentiation in cerebrospinal fluid.
    Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
    Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.